130.72
2.93%
+3.72
After Hours:
130.89
0.17
+0.13%
Merck & Co Inc stock is currently priced at $130.72, with a 24-hour trading volume of 12.03M.
It has seen a +2.93% increased in the last 24 hours and a +4.32% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $126.6 pivot point. If it approaches the $130.2 resistance level, significant changes may occur.
Previous Close:
$127.00
Open:
$129.69
24h Volume:
12.03M
Market Cap:
$331.12B
Revenue:
$60.11B
Net Income/Loss:
$365.00M
P/E Ratio:
72.62
EPS:
1.8
Net Cash Flow:
$9.14B
1W Performance:
+4.38%
1M Performance:
+4.32%
6M Performance:
+26.14%
1Y Performance:
+12.18%
Merck & Co Inc Stock (MRK) Company Profile
Name
Merck & Co Inc
Sector
Industry
Phone
908-740-4000
Address
2000 Galloping Hill Road, Kenilworth, NJ
Merck & Co Inc Stock (MRK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
Nov-09-23 | Initiated | Deutsche Bank | Buy |
Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Oct-20-23 | Upgrade | UBS | Neutral → Buy |
Jul-14-23 | Initiated | HSBC Securities | Hold |
Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Mar-06-23 | Initiated | Jefferies | Buy |
Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
Nov-18-22 | Initiated | Credit Suisse | Outperform |
Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
Jun-06-22 | Resumed | SVB Leerink | Outperform |
Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Dec-17-21 | Initiated | Goldman | Buy |
Dec-16-21 | Initiated | Daiwa Securities | Neutral |
Dec-13-21 | Downgrade | UBS | Buy → Neutral |
Dec-09-21 | Initiated | Wells Fargo | Overweight |
Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
Nov-01-21 | Upgrade | Argus | Hold → Buy |
Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-27-21 | Resumed | Truist | Buy |
May-20-21 | Downgrade | Argus | Buy → Hold |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Nov-10-20 | Resumed | Bernstein | Outperform |
Sep-29-20 | Initiated | Berenberg | Hold |
Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Feb-27-20 | Initiated | Barclays | Overweight |
Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-17-19 | Resumed | BofA/Merrill | Neutral |
Aug-16-19 | Initiated | SVB Leerink | Outperform |
Jul-03-19 | Initiated | Mizuho | Buy |
May-28-19 | Initiated | Goldman | Neutral |
May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
Oct-16-18 | Reiterated | Citigroup | Buy |
Oct-09-18 | Resumed | Guggenheim | Buy |
Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck & Co Inc Stock (MRK) Latest News
Merck (MRK) Q1 2024 Earnings Call Transcript
The Motley Fool
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Zacks Investment Research
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Benzinga
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks Investment Research
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks Investment Research
Merck & Co Inc Stock (MRK) Financials Data
Merck & Co Inc (MRK) Revenue 2024
MRK reported a revenue (TTM) of $60.11 billion for the quarter ending December 31, 2023, a +1.40% rise year-over-year.
Merck & Co Inc (MRK) Net Income 2024
MRK net income (TTM) was $365.00 million for the quarter ending December 31, 2023, a -97.49% decrease year-over-year.
Merck & Co Inc (MRK) Cash Flow 2024
MRK recorded a free cash flow (TTM) of $9.14 billion for the quarter ending December 31, 2023, a -37.83% decrease year-over-year.
Merck & Co Inc (MRK) Earnings per Share 2024
MRK earnings per share (TTM) was $0.14 for the quarter ending December 31, 2023, a -97.55% decline year-over-year.
Merck & Co Inc Stock (MRK) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Merck & Co., Inc. | 10% Owner |
Mar 11 '24 |
Buy |
23.00 |
21,397,205 |
492,135,715 |
1,000 |
Davis Robert M | Chairman, CEO & President |
Feb 14 '24 |
Option Exercise |
73.73 |
85,021 |
6,268,598 |
433,348 |
Litchfield Caroline | EVP & CFO |
Feb 14 '24 |
Option Exercise |
58.08 |
38,291 |
2,223,941 |
89,199 |
Davis Robert M | Chairman, CEO & President |
Feb 14 '24 |
Sale |
125.40 |
85,021 |
10,661,574 |
348,327 |
Litchfield Caroline | EVP & CFO |
Feb 14 '24 |
Sale |
125.50 |
38,291 |
4,805,520 |
50,908 |
Davis Robert M | Chairman, CEO & President |
Feb 13 '24 |
Option Exercise |
74.18 |
150,000 |
11,127,160 |
498,327 |
Davis Robert M | Chairman, CEO & President |
Feb 13 '24 |
Sale |
125.85 |
150,000 |
18,877,424 |
348,327 |
Romanelli Joseph | President, Human Health Int?l |
Feb 13 '24 |
Sale |
124.89 |
1,000 |
124,888 |
19,569 |
Li Dean Y | Executive VP & President, MRL |
Feb 09 '24 |
Option Exercise |
62.07 |
14,702 |
912,553 |
60,944 |
Li Dean Y | Executive VP & President, MRL |
Feb 09 '24 |
Sale |
125.50 |
14,702 |
1,845,083 |
46,242 |
About Merck & Co Inc
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., Daiichi Sankyo Company, Limited, and Cold Genesys, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Cap:
|
Volume (24h):